Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis

YILMAZ Y., Yonal O., Deyneli O., ÇELİKEL Ç., Kalayci C., DUMAN D.

ACTA GASTRO-ENTEROLOGICA BELGICA, vol.75, no.2, pp.240-244, 2012 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 75 Issue: 2
  • Publication Date: 2012
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.240-244
  • Keywords: sitagliptin, diabetes, nonalcoholic steatohepatitis, dipeptidyl peptidase-IV inhibitor, DPPIV, DIPEPTIDYL-PEPTIDASE-IV, FATTY LIVER-DISEASE, GLYCEMIC CONTROL, DPP-IV, DISTURBANCES, VILDAGLIPTIN, INHIBITION, PREVENTS, THERAPY, DIET
  • Recep Tayyip Erdoğan University Affiliated: No


Background & Aims : Preliminary evidence suggests that inhibition of dipeptidyl peptidase (DPP)-IV preserves pancreatic beta cell function in patients with type 2 diabetes (T2D). However, its effects on liver histology in nonalcoholic steatohepatitis (NASH), hepatic complication of diabetes, have not yet been adequately explored. The present open-label, single-arm observational pilot study investigated the effects of one year of treatment with a dipeptidyl peptidase-IV inhibitor, sitagliptin, on liver histology, body mass index (BMI), and laboratory parameters in NASH patients with T2D.